Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

[Attitude of primary care physicians to early detection of prostatic cancer through prostate-specific antigen].

Oller Colom M, Jiménez Navarrete S, Hidalgo García A, Calvo Rosa E, Pérez Herrera MM, Castellanos Duarte RM, Simón Muela CI, Asens Mampel N, Duaso Allué I, Gascón Gazulla S.

Aten Primaria. 2000 Sep 30;26(5):323-6. Spanish.

PMID:
11100603
2.

Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: comparison to prostatic biopsy.

Murray NP, Reyes E, Tapia P, Orellana N, Dueñas R, Fuentealba C, Badinez L.

Arch Esp Urol. 2011 Dec;64(10):961-71. English, Spanish.

PMID:
22228894
3.

Screening for prostate cancer--how to manage in 2006?

Lobel B.

Acta Chir Iugosl. 2005;52(4):19-21.

PMID:
16673588
4.

Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer.

Candas B, Cusan L, Gomez JL, Diamond P, Suburu RE, Lévesque J, Brousseau G, Bélanger A, Labrie F.

Prostate. 2000 Sep 15;45(1):19-35.

PMID:
10960839
5.

Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.

Schröder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R.

Urology. 2001 Jan;57(1):83-90.

PMID:
11164149
6.

Value of prostate-specific antigen (PSA) mass ratio in the detection of prostate cancer in men with PSA levels of ≤10 ng/mL.

Hong SK, Oh JJ, Byun SS, Hwang SI, Choo MS, Lee SE.

BJU Int. 2012 Jul;110(2 Pt 2):E81-5. doi: 10.1111/j.1464-410X.2011.10764.x.

7.

A performance analysis of the presence of malignant circulating prostate cells as a predictive factor for the detection of prostate cancer in the first, second and third prostate biopsy.

Murray NP, Reyes E, Tapia P, Badinez L, Orellana N, Fuentealba C, Olivares R, Dueñas R.

Arch Esp Urol. 2013 May;66(4):335-41. English, Spanish.

PMID:
23676536
8.

[Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)].

Cepeda Piorno J, Rivas del Fresno M, Fuente Martín E, González García E, Muruamendiaraz Fernández V, Fernández Rodríguez E.

Arch Esp Urol. 2005 Jun;58(5):403-11. Spanish.

PMID:
16078781
9.

[Is it convenient in a screening programme for prostate tumour to do biopsy in people with PSA between 3 and 3.9 ng/ml?].

Parravicini M, Del Boca C.

Arch Ital Urol Androl. 2003 Jun;75(2):99-101. Italian.

PMID:
12868147
10.

Early diagnosis of prostate cancer in the Western Cape.

Heyns CF, Naudé AM, Visser AJ, Marais DC, Stopforth HB, Nyarko JK, Stellmacher GA.

S Afr Med J. 2001 Aug;91(8):679-84.

PMID:
11584784
11.

Problems with prostate specific antigen screening for prostate cancer in the primary healthcare setting in South Africa.

Heyns CF, Mathee S, Isaacs A, Kharwa A, De Beer PM, Pretorius MA.

BJU Int. 2003 Jun;91(9):785-8.

12.

Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.

Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J.

Eur Urol. 2015 Sep;68(3):354-60. doi: 10.1016/j.eururo.2014.12.006.

PMID:
25556937
14.

[Screening for early detection of prostate cancer (first experience in Israel)].

Neheman A, Shotland Y, Metz Y, Stein A.

Harefuah. 2001 Jan;140(1):4-10, 88, 87. Hebrew.

PMID:
11242898
15.

Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.

Mäkinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, Juusela H, Määttänen L, Auvinen A.

J Urol. 2001 Oct;166(4):1339-42.

PMID:
11547069
17.

Mass screening of prostate cancer in Changchun City of China.

Li X, Tsuji I, Kuwahara M, Zhang H, Wang H, Zhang L, Ji G, Zhao X.

Int Urol Nephrol. 2004;36(4):541-8.

PMID:
15787333
18.
19.

Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff.

Luboldt HJ, Bex A, Swoboda A, Hüsing J, Rübben H; Early Detection Project Group of the German Urological Association..

Eur Urol. 2001 Feb;39(2):131-7.

PMID:
11223671
20.

Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.

Catalona WJ, Richie JP, deKernion JB, Ahmann FR, Ratliff TL, Dalkin BL, Kavoussi LR, MacFarlane MT, Southwick PC.

J Urol. 1994 Dec;152(6 Pt 1):2031-6.

PMID:
7525994

Supplemental Content

Support Center